21 Nov 2021
From TAVI to mitral and tricuspid - Applying evidence to expand patients' treatment options - Part 1 - Best long-term outcomes start with the first procedure
Sponsored by Edwards Lifesciences
Anchorperson:
B. Prendergast
Moderator:
P. MacCarthy
Summary
In this session from PCR London Valve 2021 dedicated to TAVI, mitral, and tricuspid, let's examine the issues related to the lifetime patient journey faced by many patients, starting with an analysis of severe aortic stenosis: how to identify the most important factors when considering the mode of first intervention, why building a standardized care pathway, and why reducing the risk of conduction disturbances after TAVI.
Learning Objectives
- To identify the most important factors when considering the mode of first intervention for aortic stenosis in the context of lifetime management and the updated 2021 ESC/EACTS Guidelines
- To understand the benefits of building a standardised care pathway to consistently achieve optimal clinical outcomes
- To highlight the essential need to reduce the risk of conduction disturbances after TAVI